Capital Advisors Ltd’s Neuropace NPCE Stock Holding History

Capital Advisors Ltd’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41	Closed	–	–	1216
2022 Q1	$0	Buy	+41	New	+$354	﹤0.01%	1113

Other funds holding NPCE

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

Revelation Capital Management Sausalito, California $67.4M AUM

Capital Advisors Ltd's NPCE Position: Q2 2022 in Review

Capital Advisors Ltd sold out of Neuropace (NPCE) in Q2 2022, closing a stake of 41 shares.

Capital Advisors Ltd first reported a position in NPCE in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 32 funds tracked by Wall St. Rank hold NPCE as of Q2 2022.

Capital Advisors Ltd reported no remaining Neuropace position as of Q2 2022 after selling out during the quarter.
Capital Advisors Ltd sold 41 Neuropace shares in Q2 2022.
Capital Advisors Ltd first reported a position in Neuropace in Q1 2022 and held it in 1 quarter.
Capital Advisors Ltd's Neuropace position peaked at $0 in Q1 2022.
32 funds tracked by Wall St. Rank held Neuropace as of Q2 2022.

Based on Capital Advisors Ltd's 13F filing for Q2 2022, filed 5 Aug 2022.